Description
Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality.
This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses the drugs currently in clinical trials, provides epidemiological information, and profiles the major competitors.
The information presented in this report is the result of primary and secondary research. Secondary research included data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. Primary research consisted of interviews and correspondance with company executives, clinicians, researchers and public health officials. The market forecasts are based on epidemiology, historical growth rates, probable product introductions, analyst expectations, and expert consensus.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Epidemiology
- Management of Schizophrenia
- Drugs in Development
- Market Summary
- World Market for Novel Antipsychotics
- Scope and Methodology
CHAPTER TWO: INTRODUCTION
- Schizophrenia
- Symptoms
- Economic Burden
- Causes
- Complications
- Distorted Perceptions of Reality
- Hallucinations and Illusions
- Delusions
- Incidence
- Types
CHAPTER THREE: TREATMENT OPTIONS
- Pharmacological Treatments
- Relapse Management
- Adherence
- Non-Pharmacological Treatments
CHAPTER FOUR: DRUGS IN CLINICAL TRIALS
- Newer Treatment Approaches
- Preclinical Agents
- A320436
- Dopamine D2 Partial Agonist Agent
- ORG 25543
- MEM 3454
- Clera 120
- Phase I Clinical Agents
- LY 483518
- SB 277011
- MGS 0028
- Muscarinic M1 Agonist Compound
- SGS 518
- Neboglamine
- Phase II Clinical Agents
- DAR 0100
- Palindore
- Reminertant
- Lurasidone
- Talnetant
- Phase III Clinical Agents
- Bifeprunox
- Lonasen
- Iloperidone
CHAPTER FIVE: MARKET FORECASTS
- Opportunities and Drivers
- World Market Breakdown
- 5H2 and D2 Antagonist Antipsychotic Agents
- Atypical Antipsychotic Agents
- 5H1A and D2 Partial Agonist and D2 and D3 Antagonist Agents
- Novel Antipsychotic Agents
- Geographical Breakdown of Antipsychotic Agents
CHAPTER SIX: KEY PLAYERS
- Astra Zeneca PLC
- Abbott Laboratories
- Johnson and Johnson
- Novartis AG
- Pfizer Inc.
LIST OF EXHIBITS
- Exhibit 1: Schizophrenia Cases, Geographical Breakdown
- Exhibit 2: Status of Key Late-Stage Antipsychotic Agents
- Exhibit 3: World Market for Antipsychotics Summary 2004-2009
- Exhibit 4: World Market for Antipsychotics by Geographic Segment Summary 2004-2009
- Exhibit 5: World Market for Antipsychotics by Drug Type Summary 2004-2009
- Exhibit 6: World Market for Novel Antipsychotics 2006-2009
- Exhibit 7: Schizophrenia Cases, Geographical Breakdown
- Exhibit 8: World Market for Antipsychotic Agents 2004-2009
- Exhibit 9: Expected Launch Dates of Late Stage Antipsychotic Agents
- Exhibit 10: World Market for Antipsychotics by Drug Type (5 H2 & D2 antagonists, atypical antipsychotics, 5 H1A & D2 partial agonist, D2 & D3 antagonists, and benzamides) 2004-2009
- Exhibit 11: World Market for 5H2 and D2 Antagonist Segment
- Exhibit 12: World Market for Atypical Antipsychotic Segment
- Exhibit 13: World Market for 5H1A and D2 Partial Agonist Segment
- Exhibit 14: World Market for D2 and D3 Antagonist Segment
- Exhibit 15: World Market for Novel Antipsychotic Therapies 2006-2009
- Exhibit 16: World Market for Antipsychotics by Geographic Segment (U.S., Europe, Japan, ROW) 2004-2009
